Bristol-Myers Squibb has VOLUNTARILY stopped selling Serzone (nefazodone)

September 2004

Bristol-Myers Squibb has VOLUNTARILY stopped selling Serzone (nefazodone) in the U.S.

It's already off the market in Europe and Canada.

The company is not saying...but liver toxicity seems to be part of the reason. FDA added a black box warning 2 years ago.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

a new antidepressant, Cymbalta
Cholesterol a new combo tablet, Vytorin
Diabetes Liver function tests are now required less often for patients taking Actos (pioglitazone) or Avandia (rosiglitazone)
Cardiology Does Altace (ramipril) improve survival after a heart attack better than other ACE inhibitors
Cardiology increased use of spironolactone for heart failure is causing more hospitalizations and deaths
Infectious Diseases A new quinolone, Factive, is hitting the market
Infectious Diseases The CDC is broadening the list of people who should get flu vaccine this year
Bristol-Myers Squibb has VOLUNTARILY stopped selling Serzone (nefazodone)
significant new drug for alcohol dependence called Campral
Renal & Urology Sanctura, a new drug for overactive bladder
Renal & Urology nifedipine or tamsulosin (Flomax) to help expel SMALL kidney stones
Supplements Altovis, Red Bull, Umph, and other energy supplements
Women's Health increasing levothyroxine doses by one-third as soon as pregnancy is confirmed
Women's Health pros and cons of soy for postmenopausal women
Neurology & Pain how to switch opioids